Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Institut de Recherches Internationales Servier
Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteers
- to assess the PK profile of S 38844 in healthy male volunteers after repeated escalating oral administration of a slow release (SR) formulation at 20, 40, 80 and 120 mg o.d. for 5 days each, under f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 5 ans
Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study comparing S 18886 30 mg o.d. versus aspirin 100 mg o.d. administered orally
To evaluate the short-term effects of S 18886, compared to low-dose aspirin, on platelet function in type 2 diabetic patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Effects of agomelatine on emotional experiences in depressed adults patients as compared to escitalopram
The purpose of this exploratory study is to differentiate the effect of two antidepressants, agomelatine versus escitalopram, on the emotional experiences in outpatients suffering from Major Depressiv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel groups, international study versus fluoxetine (20 mg/day with potential adjustment to 40 mg) with a double-blind extension period of 16 weeks
To assess the agomelatine superiority to fluoxetine, using the Hamilton Depression Rating Scale 17 items, after a 8-week treatment in out-patients suffering from severe Major Depressive Disorder.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (IRIS)
MAJ Il y a 4 ans
A placebo-controlled, proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis
The objective of this study is to evaluate the efficacy and safety of gevokizumab on symptoms of giant cell arteritis (GCA) in relapsing patients receiving systemic oral corticosteroids (CS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of S 38093 versus placebo in patients with mild to moderate Alzheimer’s disease
to assess the efficacy of S 38093 versus placebo after 24 weeks of treatment, on cognitive performance measured with the ADAS-Cog 11-items in patients with mild to moderate Alzheimer's disease.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks
The purpose of this trial is to assess the efficacy of agomelatine versus paroxetine on quality of the remission in elderly depressed out-patients remitted after a 12-week treatment period. Primary ob...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolic dysfunction
To compare the safety profiles of the ivabradine modified release (MR) formulation and ivabradine immediate release (IR) formulation over a 6-month period
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Oral administration of S 78454 in combination with cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant